Abeona Therapeutics : Presentation Q1 2026 PDF Q1 2026

Published: 2026-05-13 11:38:11 ET ABEO

Published on 05/13/2026 at 11:38 am EDT

Q1 2026 Results and Pipeline Update

May 13, 2026

Corporate Overview

Vishwas Seshadri, Ph.D., M.B.A.

CHIEF EXECUTIVE OFFICER, DIRECTOR

3

Six Qualified Treatment Centers activated

Three patients treated in the first quarter

Continued growth anticipated fueled by QTC expansion and positive early ZEVASKYN experiences

Radically novel engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA),

in-licensed for a $7M upfront payment

Ophthalmology programs deprioritized

$10.0

$9.0

$8.0

$7.0

$6.0

$5.0

$4.0

$3.0

$2.0

$1.0

$0.0

Net Product Revenue

$8.7

$6.3M

$2.4

Q4 2025 Q1 2026

- Millions of $USD

4

Commercial Update

Madhav Vasanthavada, Ph.D., M.B.A. CHIEF COMMERCIAL OFFICER

5

Patients Treated:

3 patients treated in the first quarter of 2026

1 patient treated so far this quarter

Patients In-queue:

1 patient biopsied (manufacturing ongoing)

6 additional patients expected to be biopsied this

quarter, 3 of whom have biopsies scheduled

Near-term ZEVASKYN potential patients:

100+ patients identified to date across QTCs and non-QTC physicians with patient referrals underway

*

6 *As of May 13, 2026

Patients treated span a wide age range, payor types, and have traveled significant distances, including out-of-state

Published coverage policies now in place for 95% of commercially insured U.S. lives; no patient attrition and no final payer denials to date

Data presentation at SID2026 on sustained wound healing and long-term safety after one-time pz-cel application: 12-year case report and 5-year Phase 3 data

7

8

8

R&D Pipeline Update

Vishwas Seshadri, Ph.D., M.B.A.

CHIEF EXECUTIVE OFFICER, DIRECTOR

9

Technical and Regulatory Expertise: Cell Therapy Commercial Excellence:

Tech transfer for manufacturing vectors and cell products

Clinical development for personalized autologous cell-therapy

Assay development, bridging and validation at every stage

BLA review and approval with heavy CMC focus

Activation of QTCs with multidisciplinary care teams

Securing market access for high-value gene therapies

Delivering personalized therapy with chain of identity

Prior oncology experience including in prostate cancer

10

PSMA is a validated target in prostate cancer, but CAR-Ts and other immunotherapies targeting PSMA have failed to deliver durable efficacy and acceptable safety profiles

PSMA SIR-TTM is a radically novel engineered T-cell technology with the potential to unlock immuno-oncology in prostate cancer

Global KOLs in prostate cancer are eager to participate in human trials with PSMA SIR-TTM

Advanced prostate cancer claims >30,000 lives in the US annually

High mortality despite advances (e.g., combinations with androgen receptor pathway inhibitors and radioligand therapies)

11

Preet M. Chaudhary M.D., Ph.D.

Professor of Medicine and Chief of Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases at University of Southern California (USC) Keck School of Medicine

Director of USC Blood and Marrow Transplant and Cell Therapy Program

Ronald Bloom Family Endowed Chair in Lymphoma Research

200+ worldwide patents (granted / pending) in the field of cell therapy

Click here to view Dr. Chaudhary's recent talk on SIR-TTM technology

12

PSMA SIR-TTM

(ABO-701)

Designed to overcome the fundamental limitations of CARs

Retains the full signaling strength, complexity, and physiological regulation of a TCR

Exceptional in vivo responses vs. CAR T cells in preclinical models, with less inflammatory cytokine release

CAR

13

CAR controls

14 Preclinicaldatageneratedinprostatetumor-bearing mice.

Financial Update

Joe Vazzano

CHIEF FINANCIAL OFFICER

15

Q1 26 net product revenue of $8.7M vs. Q4 25 net product revenue of $2.4M

Q1 26 cost of sales of $2.7M vs. Q4 25 cost of sales of $1.0M

R&D expenses of $9.6M for Q1 26 (including $7.0M license payment for PSMA SIR-TTM asset) vs. $9.9M for Q1 25

SG&A expenses of $19.5M for Q1 26 vs. $9.8M for Q1 25

$168.3M in cash, cash equivalents and short-term investments as of March 31, 2026

16

Conclusions

Vishwas Seshadri, Ph.D., M.B.A.

CHIEF EXECUTIVE OFFICER, DIRECTOR

17

Strong Leading Indicators for ZEVASKYN® Launch

Advancing PSMA SIR-TTM in Prostate Cancer

Our mission to harness the promise of genetic medicine to transform the lives of patients is inspired by our vision, to realize a world where cure is the new standard of care.

18

Questions

19

Disclaimer

Abeona Therapeutics Inc. published this content on May 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 13, 2026 at 15:37 UTC.